YIBAI PHARMACEUTICAL(SH:600594)2026-01-21 09:45Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -342 million and -285 million RMB, indicating a loss [3]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -336 million and -280 million RMB [4]. - In 2024, the total profit was -332.52 million RMB, with a net profit attributable to shareholders of -317.22 million RMB [5]. Revenue and Cost Projections - The company anticipates a 14% decline in revenue due to decreased sales of main products, despite a projected 18% decrease in costs [7]. - The company plans to recognize goodwill impairment of 110 million to 132 million RMB, which will further increase the loss [7]. Earnings Forecast and Audit Status - The earnings forecast is based on preliminary calculations and has not been audited by a registered accountant [8]. - The company emphasizes that the forecast data is preliminary and the final audited financial data will be disclosed in the 2025 annual report [9].